MX2024007288A - Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. - Google Patents

Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.

Info

Publication number
MX2024007288A
MX2024007288A MX2024007288A MX2024007288A MX2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A
Authority
MX
Mexico
Prior art keywords
antibody
methods
amyloid beta
tau
beta protofibril
Prior art date
Application number
MX2024007288A
Other languages
English (en)
Spanish (es)
Inventor
Pallavi Sachdev
Larisa Reyderman
David Li
Kristin Wildsmith
Eric Mcdade
Shobha Dhadda
Lynn Kramer
Randall Bateman
Ishani Landry
Chad Swanson
Michio KANEKIYO
Michael Irizarry
June Kaplow
David Verbel
Seiichi Hayato
Robert Gordon
Sumit Rawal
Jin Zhou
Pau Aceves Baldo
Akihiko Koyama
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2024007288A publication Critical patent/MX2024007288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
MX2024007288A 2021-12-17 2022-11-08 Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. MX2024007288A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (1)

Publication Number Publication Date
MX2024007288A true MX2024007288A (es) 2024-06-28

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007288A MX2024007288A (es) 2021-12-17 2022-11-08 Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.

Country Status (8)

Country Link
US (1) US20250051427A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547001A (cg-RX-API-DMAC7.html)
KR (1) KR20240115910A (cg-RX-API-DMAC7.html)
AU (1) AU2022410770A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242280A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007288A (cg-RX-API-DMAC7.html)
WO (1) WO2023114586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
US20250051427A1 (en) 2025-02-13
CA3242280A1 (en) 2023-06-22
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
AU2022410770A1 (en) 2024-06-13
KR20240115910A (ko) 2024-07-26
JP2024547001A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
DOP2021000199A (es) ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS
BR112022001460A2 (pt) Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
CO2023011853A2 (es) Anticuerpos anti-variable delta 1 de tcr
CO2024013569A2 (es) Moléculas de unión contra frα
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
CR20190346A (es) Conjugados de fármacos y anticuerpos anti-ccr7
BR112016030686A2 (pt) anticorpos anti tau humanizados
ECSP23003930A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilados en la serina 413
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
UY39324A (es) Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
PY2018606A (es) Anticuerpo monoclonal que se une específicamente a GITR
CL2025001214A1 (es) Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
MX2022012913A (es) Anticuerpo anti-ox40 y usos del mismo.
MX2021015501A (es) Anticuerpos y metodos de uso.
CL2023001667A1 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CA3242280A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody